167 studies found for:    "Haemophilus influenzae"
Show Display Options
Rank Status Study
1 Completed Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
Condition: Haemophilus Influenzae Type b
Intervention: Biological: Haemophilus influenzae type b
2 Completed Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b
Condition: Haemophilus Influenzae Type b
Interventions: Biological: Haemophilus influenzae type b vaccine;   Biological: Commercial Haemophilus influenzae type b vaccine
3 Completed Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in China
Condition: Haemophilus Influenzae Type b (Hib) Infection
Interventions: Biological: Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine);   Biological: Hiberix (Haemophilus influenzae type b (Hib) vaccine)
4 Completed Nontypeable H. Influenzae in Healthy Adults
Condition: Haemophilus Influenzae (NTHI)
Intervention: Biological: NTHi Strain 2019
5 Completed
Has Results
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B
Conditions: Diphtheria;   Pertussis;   Tetanus;   Hepatitis B;   Haemophilus Influenzae Infections
Intervention: Biological: Quinvaxem
6 Completed
Has Results
Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults
Conditions: Diseases Caused by Streptococcus Pneumoniae and Nontypable Haemophilus Influenzae;   Haemophilus Influenzae-Streptococcus Pneumoniae Vaccine
Interventions: Biological: GSK2231395A;   Biological: Engerix-B
7 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age
Conditions: Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014;   Biological: ActHIB;   Biological: Pediarix/Infanrix Penta
8 Terminated Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine
Conditions: Non-Typable H. Influenzae / S. Pneumoniae Infections;   Haemophilus Influenzae-Streptococcus Pneumoniae Vaccine
Interventions: Biological: GSK2231395A;   Biological: TwinrixTM
9 Completed Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean Children
Condition: Haemophilus Influenzae Type B Infection
Intervention: Biological: Haemophilus influenza type b conjugate vaccine
10 Completed Study to Eliminate Hib Carriage in Rural Alaska Native Villages
Conditions: Haemophilus Influenzae Type B;   Carrier State
Intervention: Biological: Hib conjugate vaccine (HbOC, Wyeth Vaccines)
11 Completed Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in China
Condition: Haemophilus Influenzae Type b (Hib) Infection
Intervention: Biological: Haemophilus influenzae type b (Hib) vaccine
12 Completed
Has Results
Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)
Conditions: Haemophilus Influenzae Type B;   Hepatitis B
Interventions: Biological: Comparator: Modified Process Vaccine;   Biological: Comparator: COMVAX™
13 Completed Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers
Conditions: Diphtheria;   Tetanus;   Pertussis;   Poliomyelitis;   Haemophilus Influenzae Type b
Interventions: Biological: PEDIACEL®  and Prevenar®;   Biological: Infanrix®-IPV+Hib and Prevenar®
14 Completed Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Conditions: Pertussis;   Diphtheria;   Tetanus;   Poliomyelitis;   Haemophilus Influenzae Type b
Interventions: Biological: DT5aP-IPV-Hib 5-component Pertussis vaccine;   Biological: Infanrix® -IPV+Hib
15 Not yet recruiting Persistency Study After Hib-CRM197 or Hib-TT Vaccines in Chinese Children
Conditions: Haemophilus Influenzae Type b Invasive Disease;   Gram-negative Invasive Infections
Interventions: Biological: Hib-CRM197 in V37_07E1;   Biological: Hib-TT in V37_07E1 study
16 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Conditions: Meningococcal Infection;   Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine;   Haemophilus Influenza b Infections
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014);   Biological: PedvaxHIB;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax
17 Completed
Has Results
3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Hib-MenCY-TT vaccine;   Biological: Hib-MenC-TT vaccine;   Biological: Menjugate ®;   Biological: Infanrix penta ®;   Biological: Infanrix hexa ®
18 Completed
Has Results
Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
Conditions: Meningococcal Infection;   Haemophilus Influenzae Type b Infection
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine;   Biological: ActHIB;   Biological: PedvaxHIB;   Biological: Pediarix;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax
19 Completed Immunogenicity and Safety Study of LBVH0101 in Healthy Infants at Two, Four and Six Months of Age
Condition: Infectious Disease by Haemophilus Influenzae Type b
Interventions: Biological: LBVH0101 (Hib vaccine);   Biological: Hiberix™ Vaccine
20 Terminated Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.
Conditions: Haemophilus Influenzae Type b;   Poliomyelitis;   Hepatitis B;   Serogroup C Meningococcal Diseases;   Diphtheria;   Pertussis;   Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccines;   Tetanus
Interventions: Biological: GSK2202083A vaccine;   Biological: Infanrix hexa;   Biological: Menjugate

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years